Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Treating patients with multiple myeloma in Ireland

Philip Murphy • 1 Sep 2022
Multiple Myeloma Belantamab mafodotin Daratumumab Selinexor

Philip Murphy, MD, Beaumont Hospital, Dublin, Ireland, highlights the advances in treatment for multiple myeloma in recent years and the current treatment landscape for patients in Ireland who are newly diagnosed and those with relapsed/refractory (R/R) disease. This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Philip Murphy

Ongoing trials in multiple myeloma in Ireland 1:28
Ongoing trials in multiple myeloma in Ireland
Philip Murphy • 1 Sep 2022
Highlights from IMS 2022 2:10
Highlights from IMS 2022
Philip Murphy • 1 Sep 2022
Treating patients with relapsed/refractory myeloma in Ireland 1:24
Treating patients with relapsed/refractory myeloma in Ireland
Philip Murphy • 1 Sep 2022
Challenges for HCPs in Ireland treating multiple myeloma 0:50
Challenges for HCPs in Ireland treating multiple myeloma
Philip Murphy • 1 Sep 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals